News & Updates

Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.

Exclusionary testing, involving upfront testing for EGFR and ALK followed by next-generation sequencing (NGS) for other genomic alterations (GAs), is the most efficient and cost-saving molecular testing strategy for patients with metastatic non-small-cell lung cancer (NSCLC) in Hong Kong and perhaps East Asia, researchers from the Chinese University of Hong Kong (CUHK) have reported.

Trastuzumab deruxtecan (T-DXd) reduces the risk of disease progression or death by 72 percent vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer whose disease progressed during or after treatment with an anti–HER-2 antibody, the first interim analysis of the DESTINY-Breast03 trial has shown.

In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.